But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" exper ...

Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...

The combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, has proven successful ...

A large clinical trial in China (HARMONi-6) found that a new immunotherapy drug, ivonescimab, may help patients with advanced ...

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...

New immunotherapy drug combinations are significantly extending survival for patients with advanced kidney cancer, one of the fastest-growing cancers in the United States, according to oncologists and ...

AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...

“In our clinical trial, we compared two different combinations of immunotherapy drugs to using a single immunotherapy drug, and found that either combination regimen doubled or tripled the response ...

FDA approval establishes durvalumab plus BCG induction and maintenance as a new immunotherapy-based option for BCG-naïve, high-risk NMIBC following TURBT, potentially redefining the frontline ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant combination immunotherapy regimens produced higher pathologic response rates than monotherapy in a ...

Blood test shows potential for noninvasive monitoring of tumor microenvironment changes and emerging treatment resistance in ...

New results from a multicenter clinical trial show that combining immunotherapy drugs nivolumab and ipilimumab significantly improves treatment response in patients with advanced and ...